NCT01762761 - Eltrombopag Phase III Study In Chinese Chronic ITP Patients | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

February 18, 2013

Primary Completion Date

June 5, 2014

Study Completion Date

November 22, 2018

Conditions

Purpura, Thrombocytopenic, Idiopathic and Hepatitis C

Interventions

DRUG

eltrombopag

TPO-R agonist

DRUG

placebo

Trial Locations (18)

100034

Novartis Investigative Site, Beijing

100044

Novartis Investigative Site, Beijing

100083

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

200025

Novartis Investigative Site, Shanghai

210029

Novartis Investigative Site, Nanjing

215006

Novartis Investigative Site, Suzhou

250012

Novartis Investigative Site, Jianan

300020

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

330006

Novartis Investigative Site, Nanchang

350001

Novartis Investigative Site, Fuzhou

410013

Novartis Investigative Site, Changsha

510080

Novartis Investigative Site, Guangzhou

510515

Novartis Investigative Site, Guangzhou

528403

Novartis Investigative Site, Zhongshan

610041

Novartis Investigative Site, Chengdu

Unknown

Novartis Investigative Site, Shanghai